Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer.
Adenocarcinoma
/ drug therapy
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents
/ therapeutic use
Esophagogastric Junction
/ drug effects
Female
Follow-Up Studies
Humans
Male
Middle Aged
Prognosis
Retrospective Studies
Salvage Therapy
Stomach Neoplasms
/ drug therapy
Survival Rate
Ramucirumab
Drug therapy
Ramucirumab
Salvage therapy
Stomach neoplasms
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
21 Apr 2020
21 Apr 2020
Historique:
received:
01
11
2019
accepted:
14
04
2020
entrez:
23
4
2020
pubmed:
23
4
2020
medline:
13
1
2021
Statut:
epublish
Résumé
Ramucirumab monotherapy as a second-line treatment for advanced gastric cancer (AGC) prolongs survival compared to the best supportive care. However, in clinical practice, ramucirumab monotherapy is sometimes used as third- or later-line treatment for AGC refractory to fluoropyrimidine and taxanes. This study evaluated the efficacy and safety of salvage-line ramucirumab monotherapy for treating AGC. The subjects of this retrospective study were advanced gastric or gastro-esophageal junction adenocarcinoma patients who received ramucirumab monotherapy after failure of 2 or more prior regimens containing fluoropyrimidine and taxanes but not ramucirumab. From June 2015 to April 2017, 51 patients were enrolled. The median progression-free survival (PFS) and overall survival (OS) were 1.8 (95% confidence interval [CI] = 1.6-2.2) and 5.1 (95% CI = 4.0-6.8) months, respectively. The objective response and disease control rates were 2 and 17%, respectively. Grade 3 adverse events (AEs; e.g., anemia, fatigue, hypertension, proteinuria, intestinal bleeding) occurred in seven (13%) patients, but no grade 4 AEs and treatment-related deaths were observed. A neutrophil-lymphocyte ratio (NLR) of < 2.5 and previous gastrectomy were associated with better PFS. Salvage-line ramucirumab monotherapy has acceptable toxicity and comparable efficacy to second-line treatment; therefore, we consider physicians might choose this therapy as a salvage-line treatment option for AGC refractory to the standard therapies.
Sections du résumé
BACKGROUND
BACKGROUND
Ramucirumab monotherapy as a second-line treatment for advanced gastric cancer (AGC) prolongs survival compared to the best supportive care. However, in clinical practice, ramucirumab monotherapy is sometimes used as third- or later-line treatment for AGC refractory to fluoropyrimidine and taxanes. This study evaluated the efficacy and safety of salvage-line ramucirumab monotherapy for treating AGC.
METHODS
METHODS
The subjects of this retrospective study were advanced gastric or gastro-esophageal junction adenocarcinoma patients who received ramucirumab monotherapy after failure of 2 or more prior regimens containing fluoropyrimidine and taxanes but not ramucirumab.
RESULTS
RESULTS
From June 2015 to April 2017, 51 patients were enrolled. The median progression-free survival (PFS) and overall survival (OS) were 1.8 (95% confidence interval [CI] = 1.6-2.2) and 5.1 (95% CI = 4.0-6.8) months, respectively. The objective response and disease control rates were 2 and 17%, respectively. Grade 3 adverse events (AEs; e.g., anemia, fatigue, hypertension, proteinuria, intestinal bleeding) occurred in seven (13%) patients, but no grade 4 AEs and treatment-related deaths were observed. A neutrophil-lymphocyte ratio (NLR) of < 2.5 and previous gastrectomy were associated with better PFS.
CONCLUSIONS
CONCLUSIONS
Salvage-line ramucirumab monotherapy has acceptable toxicity and comparable efficacy to second-line treatment; therefore, we consider physicians might choose this therapy as a salvage-line treatment option for AGC refractory to the standard therapies.
Identifiants
pubmed: 32316940
doi: 10.1186/s12885-020-06865-7
pii: 10.1186/s12885-020-06865-7
pmc: PMC7175590
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
338Références
Oncology. 2007;73(3-4):215-20
pubmed: 18424885
Arch Surg. 1999 Dec;134(12):1325-31; discussion 1331-2
pubmed: 10593330
Cancer Chemother Pharmacol. 2017 Sep;80(3):575-582
pubmed: 28730292
Dig Surg. 2014;31(4-5):327-33
pubmed: 25471697
Oncotarget. 2018 Oct 2;9(77):34520-34527
pubmed: 30349646
Br J Cancer. 2011 Apr 12;104(8):1288-95
pubmed: 21448173
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
J Gastric Cancer. 2017 Jun;17(2):132-144
pubmed: 28680718
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Lancet. 2014 Jan 4;383(9911):31-39
pubmed: 24094768
J Immunol. 1985 Jan;134(1):230-4
pubmed: 3871101
J Thorac Oncol. 2015 Feb;10(2):280-5
pubmed: 25299234
Gastric Cancer. 2014 Oct;17(4):703-10
pubmed: 24442663
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Ann Oncol. 2018 Apr 1;29(4):924-930
pubmed: 29324972
Onkologie. 2012;35(4):176-83
pubmed: 22488087
Lancet Oncol. 2009 Nov;10(11):1063-9
pubmed: 19818685
Ann Oncol. 2009 Apr;20(4):666-73
pubmed: 19153121
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Br J Cancer. 2007 Mar 26;96(6):891-5
pubmed: 17375036
Gastric Cancer. 2018 Sep;21(5):819-830
pubmed: 29427038
Br J Cancer. 2016 Oct 11;115(8):974-982
pubmed: 27623234
J Immunother Cancer. 2018 Oct 11;6(1):106
pubmed: 30314524
Lung Cancer. 2017 Apr;106:1-7
pubmed: 28285682
Gastric Cancer. 2018 Sep;21(5):831-844
pubmed: 29397460
Lancet Oncol. 2008 Mar;9(3):215-21
pubmed: 18282805
Gastric Cancer. 2018 Nov;21(6):1041-1049
pubmed: 29508095
BMC Cancer. 2013 Jul 22;13:350
pubmed: 23876227
Sci Rep. 2015 Jul 31;5:11026
pubmed: 26226887
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686
J Clin Oncol. 2019 May 20;37(15):1296-1304
pubmed: 30925125
Int J Clin Oncol. 2018 Feb;23(1):92-97
pubmed: 28913565